MedTrace Logo

Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study

NCT07134738 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2026-01-16

No results posted yet for this study

Summary

A multicenter, open-label, non-interventional study evaluates the safety and tolerability of oral Dimolegin® (60 mg once daily) for thromboprophylaxis in hospitalized adults (≥18 years) with moderate COVID-19 in real clinical pratice. The primary objective is to assess safety and tolerability of Dimolegin® in preventing thrombotic complications.

Conditions

Interventions

DRUG

Dimolegin

Dimolegin® is administered orally once daily,The recommended dose is 60 mg (six 10 mg tablets) once daily.

Sponsors & Collaborators

  • Avexima Diol LLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-07
Primary Completion
2025-01-15
Completion
2025-01-15

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07134738 on ClinicalTrials.gov